Method for restoring depleted purine nucleotide pools

Abstract

A method of increasing the rate of repletion of purine nucleotide pools in tissue deficient in the nucleotides, which comprises administering to a human or animal a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside, 5-amino-4-imidazolecarboxamide, or a pharmaceutically acceptable salt thereof sufficient to increase the rate of the repletion is disclosed along with pharmaceutical compositions useful for carrying out the method of the invention.

What is claimed as new and desired to be secured by Letters Patent of the United States: .[.1. A method of increasing the rate of repletion of adenosine triphosphate and guanosine triphosphate nucleotides in a tissue deficient in said nucleotides, which comprises: 
     
        salt thereof sufficient to increase the rate of said repletion..]. .[.2. The method of claim 1, wherein said amount is from 0.1 to 2.0 μmole/min/kg..]. .[.3. The method of claim 1, wherein said amount is from 0.2 to 1.0 μmole/min/kg..]. .[.4. The method of claim 1, wherein said compound is 5-amino-4-imidazolecarboxyamide riboside..]. .[.5. The method of claim 4, wherein the amount of said compound is from 0.2 to 1.0 μmole/min/kg..]. .[.6. The method of claim 1, wherein said administering is to a tissue in a human..]. .[.7. The method of claim 6, wherein said tissue is myocardial tissue..]. .[.8. The method of claim 7, wherein said compound is administered in an amount of from 0.2 to 1.0 μmole/min/kg..]. .[.9. The method of claim 1, wherein said administering is to a tissue maintained outside a human or animal body..]. .[.10. The method of claim 9, wherein said amount is from 0.1 to 2.0 μmole/min/kg..]. .[.11. The method of claim 9, wherein said amount is from 0.2 to 1.0 μmole/min/kg..]. .[.12. The method of claim 9, wherein said compound is 5-amino-4-imidazolecarboxamide riboside..]. .[.13. The method of claim 12, wherein the amount of said compound is from 0.2 to 1.0 μmole/min/kg..]. .[.14. The method of claim 9, wherein said tissue comprises part of a human organ..]. .[.15. The method of claim 14, wherein said organ is a kidney, heart, liver, or pancreas..]. .[.16. The method of claim 1, wherein said administering is to a human afflicted with 
     
     
        Lesch-Nyhan Syndrome..]. .Iadd.17.  A method of treating an ischemic condition in a human comprising the step of administering a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside or a pharmaceutically acceptable salt thereof during and after ischemia wherein said ischemic condition is a myocardial ischemia. .Iaddend. .Iadd.18. A method comprising the administration of a therapeutically effective amount of 5-amino-4-imidazolecarboxamide 
     
     
        riboside during coronary bypass surgery in a human. .Iaddend. .Iadd.19.  A method of treating an ischemic condition in a human comprising the step of administering a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside or a pharmaceutically acceptable salt thereof during and after ischemia wherein said ischemic condition is a myocardial ischemia caused by a coronary occlusion. .Iaddend. .Iadd.20. A method of treating an ischemic condition in a human comprising the step of administering a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside or a pharmaceutically acceptable salt thereof during and after ischemia wherein said ischemic condition is a myocardial ischemia caused by a myocardial infarction. .Iaddend. .Iadd.21. A method of treating an ischemic condition in a human comprising the step of administering a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside or a pharmaceutically acceptable salt thereof during and after ischemia wherein said ischemic condition is angina. .Iaddend. .Iadd.22. A method of treating an ischemic condition in a human comprising the step of administering a therapeutically effective amount of 5-amino-4-imidazolecarboxamide riboside or a pharmaceutically acceptable salt thereof during and after ischemia wherein said myocardial ischemia is caused by a coronary occlusion and wherein said 5-amino-4-imidazolecarboxamide riboside is administered following thrombolysis for said coronary occlusion. .Iaddend.